Lyophilized vial
GLP1-SG
Long-acting GLP-1 receptor agonist analogue for metabolic pathway studies.
$160.00
GLP-1 Was the Beginning. GLP-3 Expands the Research.
For Research Use Only. Not for Human Consumption.
GLP Research · Metabolic
GLP3-RT
99.91% purity · Lot K3BQAA · tested Jun 11, 2026Triple-agonist peptide studied at the GLP-1, GIP and glucagon receptors.
- Independently tested
- Lot-matched COA
- Lyophilized for stability
- Ships from the USA
Research use only. Not for human or veterinary use. Sold to qualified researchers aged 21+.
SizePO-GLP3RT-10
$110.00
1
Lot-matched documentation. Every order ships with the certificate for its lot. If a vial arrives damaged or doesn't match its paperwork, tell us within 72 hours and we'll replace it.
Latest lab results
Third-party testedGLP3-RT 10 mg
- Purity (HPLC-UV)
- 99.91%
- Identity (LC-MS)
- Confirmed — GLP-3
- Net content
- 10.96 mg (label 10 mg)
- Lot
- K3BQAA
- Tested
- Jun 11, 2026
- Lab
- Freedom Diagnostics Testing
Your order ships with the certificate for its own lot. 2 earlier certificates for this size in the COA library.
About GLP3-RT
Triple-agonist peptide studied at the GLP-1, GIP and glucagon receptors.
Supplied as
10 mg per vial, as a lyophilized powder in a sealed glass vial with a crimped cap. The lot number on the label matches the certificate of analysis in the COA library.
Storage and handling
Store lyophilized powder frozen (−20 °C) or refrigerated, sealed and away from light. Once reconstituted, keep refrigerated (2–8 °C).
Handle in a laboratory setting using appropriate protective equipment. Consult the certificate of analysis and safety data for lot-specific information.
Important research notice. This product is intended solely for in-vitro and laboratory research. It is not a drug, food, supplement or cosmetic, has not been evaluated by the FDA, and must not be used in humans or animals. Peptides Only does not provide usage or dosing information.
Research summary
GLP3-RT is a 39-residue lipidated peptide studied as a triple agonist at the GLP-1, GIP and glucagon receptors. It is supplied for laboratory research into multi-receptor incretin signalling, energy expenditure and hepatic lipid metabolism.
What is a triple-agonist peptide?
Triple agonists combine activity at three related class B G protein-coupled receptors in one molecule: the two incretin receptors (GLP-1 and GIP) and the glucagon receptor2,3. They are engineered from a hybrid peptide backbone, with a fatty-acid side chain for albumin binding and a long half-life.
The rationale is that each receptor contributes something different. GLP-1 and GIP receptor signalling act on insulin secretion and appetite; glucagon receptor signalling raises energy expenditure and drives hepatic fat oxidation, while the incretin activity offsets glucagon's tendency to raise blood glucose3.
What triple-agonist research examines
Limitations of the evidence
The balance of activity across the three receptors differs between molecules, so findings for one triple agonist do not transfer automatically to another. This research compound is not a medicine, has not been evaluated by the FDA, and is sold for laboratory research only.
GLP3-RT FAQ
Which receptors does GLP3-RT act on?
Three: the GLP-1 receptor, the GIP receptor and the glucagon receptor2,3.
Why include glucagon receptor activity?
In research models, glucagon receptor signalling increases energy expenditure and hepatic fat oxidation; pairing it with incretin receptor activity counters glucagon's effect on blood glucose3.
Which sizes are available?
10 mg, 30 mg, 48 mg and 60 mg vials of lyophilized peptide, each lot with its own certificate.
How should a lyophilized GLP research peptide be stored?
Sealed vials of lyophilized peptide are kept frozen (−20 °C) or refrigerated, dry and away from light. Peptide storage and stability explains why.
How is each lot verified?
Every lot is tested by an independent laboratory for identity (mass spectrometry) and purity (HPLC). The certificate for the lot on your vial is published in the COA library and linked from this page.
References
- Baggio LL, Drucker DJ. Biology of incretins: GLP-1 and GIP. Gastroenterology. 2007;132(6):2131-57. PubMed 17498508
- Müller TD, Finan B, Bloom SR, et al. Glucagon-like peptide 1 (GLP-1). Mol Metab. 2019;30:72-130. PubMed 31767182
- Finan B, Yang B, Ottaway N, et al. A rationally designed monomeric peptide triagonist corrects obesity and diabetes in rodents. Nat Med. 2015;21(1):27-36. PubMed 25485909
Research summary reviewed 2026-10-26 against the cited literature.
Why GLP3-RT
Triple-Pathway Research
Targets GLP-1, GIP, and glucagon receptors rather than GLP-1 alone.
Broader Metabolic Signaling
Designed to investigate multiple pathways involved in energy balance and metabolic function.
Promising Clinical Research
Triple-receptor agonists like GLP3-RT are among the most closely watched compounds in metabolic research.
Next-Generation Approach
Combines three receptor mechanisms within a single investigational compound.
For Research Use Only. Not for Human Consumption.
GLP3-RT research
Beyond GLP-1: Multi-Pathway Research Starts Here.
The Next Evolution in Metabolic Research
Move beyond single-pathway GLP-1 research and investigate the potential of multi-receptor activity.
One Compound. Multiple Research Pathways.
Explore the next generation of metabolic research beyond traditional GLP-1 models.
Three Research Pathways. One Compound. A New Frontier.
More Pathways. More Research Possibilities.
Built for researchers exploring metabolic signaling beyond conventional GLP-1 models.
For Research Use Only. Not for Human Consumption.
Contact Peptides Only
Operated by DND Wellness LLC · 1309 Coffeen Ave, Suite 1200, Sheridan, WY 82801.
support@peptides-only.com · (508) 404-8124
Use the chat widget to ask a question. Informational and promotional text messages require separate, optional consent. Message frequency varies. Msg & data rates may apply. Reply STOP to unsubscribe or HELP for help. Consent is not a condition of purchase. 21+.
SMS consent & support · SMS terms & Terms of Service · Privacy Policy